Acute myeloid leukemia
Conditions
Interventions
Control group:None
Experimental group:rhTHP treatment after chemotherapy
Sponsors
First Affiliated Hospital, College of Medcine, Zhejiang University
Eligibility
Sex/Gender
All
Age
18 Years to 60 Years
Inclusion criteria
Inclusion criteria: 1. Patients with AML confirmed by WHO classification (except M3) and patients who achieved complete remission after induction therapy; 2. Aged 18 to 60 years; 3. The ECOG score 0-2 when selected; 4. Liver and kidney function: blood bilirubin 50%; 6. Can provide informed consent, can understand and comply with the requirements of the study.
Exclusion criteria
Exclusion criteria: 1. Acute promyelocytic leukemia; 2. History of other malignant tumors in the past 5 years; 3. HIV positive; 4. Other serious diseases that may limit the patient's participation in this trial (such as advanced infection, uncontrolled diabetes, severe cardiac insufficiency or angina pectoris, etc.); 5. The general condition is not suitable for chemotherapy; 6. Pregnant or lactating women; 7. Secondary to myeloproliferative disease or treatment-related AML.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Days of platelet < 20×10^9/L; | — |
Secondary
| Measure | Time frame |
|---|---|
| Days of platelet < 50×10^9/L;The lowest level of platelet;Bleeding events;Platelet transfusion volume;Security; | — |
Countries
China
Contacts
Public ContactZhu Honghu
First Affiliated Hospital, College of Medcine, Zhejiang University
Outcome results
None listed